aTyr Pharma Overview
Pro stress-test →aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. The company's primary focus is efzofitimod (ATYR1923), a clinical-stage product candidate designed to down-regulate immune engagement in severe inflammatory lung diseases.
Strategic Profile
Pro stress-test →The company was founded in 2005 and is headquartered in San Diego, California. aTyr has scheduled an FDA Type C Meeting for mid-April 2026 to review Phase 3 EFZO-FIT study results from pulmonary sarcoidosis. aTyr has a partnership with Kyorin Pharmaceutical with a total deal value up to $175M for development and commercialization of efzofitimod for ILD in Japan.
Competitive Landscape
Pro stress-test →aTyr competes in the orphan lung disease therapeutic space with companies developing immunomodulatory and anti-fibrotic agents. The company's proprietary tRNA synthetase platform provides differentiation, though competitors in ILD treatment include established players focused on pirfenidone and nintedanib mechanisms. First-mover advantage in NRP2 modulation provides competitive positioning.
Industry Context
aTyr Pharma operates in Biopharmaceutical - Orphan/Rare Disease.
Key facts
Founded: 2005 · Headquarters: San Diego, United States · Employees: 49